BioNTech and Pfizer expect to be able to manufacture up to 100m doses of the vaccine by the end of the year, and more than 1.2bn doses by the end of 2021, depending on the dosage sizes required.
Full article: https://www.ft.com/content/65d0b33a-f12a-4878-ac87-da4835683949